Blog

A deep dive into next-generation sequencing topics including G4 Sequencing Platform technology, key applications, and the innovations driving a new era in the space.

LATEST BLOG

ABRF 2024: In-Situ Sequencing: Enabling Spatial Biology at Scale

Rahul Lodhavia, Product Manager, and Sabrina Shore, Associate Director, Sequencing Applications, recently spoke at the Association of Biomolecular Resource Facilities Annual Meeting in Minneapolis, MN. This blog summarizes their talk and provides information about pioneering breakthroughs in next-generation sequencing and spatial multiomics from Singular Genomics.

Read More

Past Blogs

That’s A Wrap From AGBT

The G4 Sequencing Platform features an Adaptive Sequencing Capacity and generates results in under 24 hours, enabling core labs to sequence experiments daily with unparalleled operational efficiency.

READ THE BLOG

ABRF 2024: In-Situ Sequencing: Enabling Spatial Biology at Scale

Rahul Lodhavia, Product Manager, and Sabrina Shore, Associate Director, Sequencing Applications, recently spoke at the Association of Biomolecular Resource Facilities Annual Meeting in Minneapolis, MN. This blog summarizes their talk and provides information about pioneering breakthroughs in next-generation sequencing and spatial multiomics from Singular Genomics.

Read More

That’s A Wrap From AGBT

The G4 Sequencing Platform features an Adaptive Sequencing Capacity and generates results in under 24 hours, enabling core labs to sequence experiments daily with unparalleled operational efficiency.

READ THE BLOG

Stay up-to-date on the latest Singular Genomics blogs!

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Max Reads Application Note